曲美他嗪联合注射用重组人脑利钠肽治疗慢性缺血性心力衰竭的效果

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (513 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection in the treatment of chronic ischemic heart failure. Methods Eighty patients with chronic ischemic heart failure hospitalized in the First Hospital of Dandong City from October 2016 to October 2019 were selected as research objects, and they were divided into control group (Trimetazidine treatment, 40 cases) and observation group (Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection treatment, 40 cases) according to the method of random number table. Both groups were treated for 7 days, and the efficacy and adverse reactions of two groups were compared. Left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), stroke volume (SV), cardiac output (CO), left ventricular ejection fraction (LVEF), serum superoxide dismutase (SOD), malondialdehyde (MDA) levels before and after treatment were compared between two groups. Results Total effective rate of observation group was significantly higher than that of control group (P < 0.05). After treatment, LVEDD and LVESD of two groups were shorter than those before treatment, SV and CO were more than those before treatment, LVEF was higher than that before treatment (P < 0.05), and LVEDD and LVESD of observation group were shorter than those of control group, SV and CO were more than those of control group, LVEF was higher than that of control group (P < 0.05). After treatment, serum SOD level of two groups was higher than that before treatment, MDA level was lower than that before treatment (P < 0.05), and serum SOD level of observation group was higher than that of control group, while MDA level was lower than that of control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection has a significant effect on chronic ischemic heart failure, which can significantly improve the cardiac function and oxidative stress state of patients, and have a good safety.

Key words： Trimetazidine Recombinant Human Brain Natriuretic Peptide for Injection Chronic ischemic heart failure Cardiac function Oxidative stress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Chunlei ZHANG Dan WANG Guidong

Cite this article:

WANG Chunlei ZHANG Dan WANG Guidong. Effect of Trimetazidine combined with Recombinant Human Brain Natriuretic Peptide for Injection in the treatment of chronic ischemic heart failure[J]. 中国医药导报, 2020, 17(20): 59-61.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I20/59

[1] 钱海燕，黄觊，胡志成，等.伊伐布雷定治疗老年心力衰竭患者的疗效观察[J].中华老年医学杂志，2017，36（2）：121-125.
[2] 宋韵，闫伟，任骞.心脏康复运动对慢性心力衰竭患者预后的影响[J].陕西医学杂志，2017，46（2）：241-242.
[3] 李兵强，王耀辉，宗雪梅，等.左西孟旦在行经皮冠状动脉介入治疗缺血性心力衰竭中的应用[J].中国综合临床，2017，33（9）：807-811.
[4] 姚亚军，陈维明，施益忠，等.米力农联合西地兰治疗慢性心力衰竭的疗效评估[J].安徽医药，2017，21（10）：1900-1903.
[5] 李若淳，钟璟，林明春，等.阿托伐他汀钙联合曲美他嗪对心力衰竭患者CRP、IL-6、RDW及BNP水平的影响[J].贵州医科大学学报，2017，42（10）：1172-1175.
[6] 杨曼，石磊.新活素的临床应用进展[J].中国临床医生杂志，2017，45（2）：23-25.
[7] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-119.
[8] 贾雄燕.血清学指标在心衰患者NYHA心功能分级中的诊断意义[J].延安大学学报：医学科学版，2015，13（3）：16-18.
[9] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：48.
[10] 于彤彤，刘双双，王菁菁，等.慢性心力衰竭患者在临床特点及危险因素方面的性别差异[J].山东医药，2015， 55（12）：49-51.
[11] 陈辰，胡松.盐酸曲美他嗪联合米力农治疗老年心衰患者的临床疗效研究[J].新疆医科大学学报，2019，42（7）：883-886.
[12] 冯亚敏，韩艳.美他嗪联合阿托伐他汀治疗慢性心力衰竭对蛋白尿的影响分析[J].山西医药杂志，2018，47（12）：1385-1388.
[13] 乔锐，乔峰，李春辉.曲美他嗪治疗扩张型心肌病心力衰竭研究现况及进展[J].临床军医杂志，2018，46（7）：837-839.
[14] 李健，周鑫玲.养心氏片联合比索洛尔治疗冠心病心力衰竭的临床研究[J].世界中医药，2019，14（12）：3278-3281.
[15] 张义全，雷芳，陈亮，等.心脉隆注射液联合芪苈强心胶囊对老年慢性心力衰竭患者血清BNP、NF-κB及胱抑素C水平的影响[J].西部中医药，2018，31（2）：1-5.
[16] 熊挺淋，张丽莎，刘涛，等.曲美他嗪对缺血性心肌病伴心力衰竭患者心功能的影响[J].中国老年学杂志，2019， 39（18）：4382-4384.
[17] 王建，肖国胜，王斌，等.心外膜左心室重建术对前间壁瘢痕形成的缺血性心力衰竭患者的短期安全性及疗效评价[J].中国介入心脏病学杂志，2018，26（1）：31-35.
[18] 杨曼，石磊.新活素的临床应用进展[J].中国临床医生杂志，2017，45（2）：23-25.
[19] 薛茫，胡桃红.新活素对急性心肌梗死后顽固性心力衰竭患者心功能的影响及临床疗效的观察[J].中国医药导报，2019，16（10）：154-156，161.
[20] 史景柏.培哚普利联合坎地沙坦对慢性心衰患者氧化应激损伤及心功能的影响[J].国际医药卫生导报，2018， 24（1）：97-99.
[21] 邹清梅，刘瑶，高金全，等.盐酸曲美他嗪对冠状动脉粥样硬化性心脏病心力衰竭患者疗效和对氧化应激及血液流变学的影响[J].中国医药，2015，10（8）：1112-1115.
[22] 穆怀彬，高峻，林琳，等.尼可地尔联合国产重组人脑利钠肽对AMI急诊PCI术后慢血流患者红细胞渗透脆性及氧化应激损伤的影响[J].临床心血管病杂志，2019， 35（1）：83-87.
[23] 王皓霖，胡黎文，张金龙，等.真武汤合桂枝茯苓丸治疗肾阳虚型慢性心力衰竭42例[J].西部中医药，2019，32（2）：95-98.
[24] 陈振岭，郑玉水，李为，等.厄贝沙坦联合心宝丸治疗老年慢性心力衰竭合并窦性心动过缓的临床效果[J].中国医药导报，2018，15（2）：54-57.
[25] 赵丽智，王飞，王曙光，等.冻干重组人脑利钠肽治疗顽固性心力衰竭合并肺动脉高压患者的短期疗效观察[J].安徽医药，2018，22（4）：757-761.